Related Experiment Videos
Aspirin and secondary mortality after myocardial infarction
Insights
Aspirin use after myocardial infarction (MI) showed a trend toward reduced mortality and fewer cardiovascular events. While not statistically significant, the study suggests potential benefits of aspirin in preventing death and recurrent ischemic heart disease (IHD).
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Myocardial infarction (MI) poses a significant risk of mortality and recurrent ischemic heart disease (IHD).
- Secondary prevention strategies are crucial for improving outcomes in post-MI patients.
Purpose of the Study:
- To evaluate the efficacy of aspirin in preventing death and reducing ischemic events in patients following a confirmed myocardial infarct.
- To assess the impact of long-term aspirin therapy on overall mortality and IHD-related morbidity.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 1682 patients with confirmed MI.
- Patients received aspirin (300 mg three times daily) or placebo for one year.
- Enrollment occurred within 7 days of infarction for 75% of participants.
Main Results:
- Total mortality was 12.3% in the aspirin group versus 14.8% in the placebo group, a non-significant 17% reduction.
- A 22% reduction in specific ischemic heart disease (IHD) mortality was observed with aspirin.
- A 28% reduction in combined total mortality and IHD morbidity (rehospitalization for MI) was noted.
Conclusions:
- Aspirin therapy following myocardial infarction demonstrated a trend towards reduced mortality and IHD events.
- While not reaching statistical significance, the observed reductions suggest a potential benefit of aspirin in secondary prevention.
- Further research may be warranted to confirm the clinical significance of these findings.
Abstract:
A randomised controlled double-blind trial of aspirin in the prevention of death was conducted in 1682 patients (including 248 women) who had had a confirmed myocardial infarct (MI). 25% of the patients were admitted to the trial within 3 days of the infarction and 50% within 7 days. Aspirin, 300 mg three times daily, was given for 1 yr. Total mortality was 12.3% in patients given aspirin and 14.8% in those given placebo, a reduction by aspirin of 17%, which was not statistically significant at p less than 0.05. The reduction in specific ischaemic-heart-disease (IHD) mortality was 22% and in total mortality plus IHD morbidity (readmission to hospital for MI in survivors) was 28%.